This inventor holds 1 USPTO granted patent. Top assignees: Seed Company Limited, Senju Pharmaceutical Co., Ltd.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2015
Title: Osamu Sakai: Innovator in Hydrogel Contact Lens Technology
Introduction
Osamu Sakai is a notable inventor based in Kobe, Japan. He has made significant contributions to the field of ophthalmic devices, particularly through his innovative work on hydrogel contact lenses. His inventions focus on enhancing drug delivery methods while providing vision correction.
Latest Patents
Sakai holds a patent for a hydrogel contact lens designed for sustained drug release. The patent, titled "Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release," describes a hydrogel that can release an anionic medicament, such as an allergy-treating agent, in a mildly irritating and effective manner. This invention not only addresses the need for effective drug delivery but also ensures that users can achieve vision correction simultaneously. The hydrogel comprises ionic monomers, including at least a cationic monomer and an anionic monomer, with specific ratios to optimize performance.
Career Highlights
Throughout his career, Osamu Sakai has worked with reputable companies, including Seed Company Limited and Senju Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of contact lens technology.
Collaborations
Sakai has collaborated with notable colleagues, including Takao Sato and Toru Matsunaga. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Osamu Sakai's work in hydrogel contact lens technology exemplifies the intersection of innovation and practical application in the medical field. His contributions continue to influence the way drug delivery is approached in ophthalmology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile